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Context—Randomized trials suggest adjuvant chemotherapy is effective for elderly patients with
stage III colon cancer. However, the elderly are less likely to receive this therapy than younger
patients, perhaps because of concern about adverse effects.
Objective—To evaluate adjuvant chemotherapy use and outcomes for older patients with stage
III colon cancer from well-defined population-based settings and healthcare systems.
Design—Observational study of adjuvant chemotherapy use and outcomes by age, using Poisson
regression to estimate the number of adverse events adjusted for demographic and clinical factors,
including comorbid illness and specific elements of chemotherapy regimens documented with
clinically detailed medical record reviews and patient and surrogate surveys.
Setting—Five geographically defined regions (Alabama, Iowa, Los Angeles County, Northern
California, and North Carolina), five integrated health-care delivery systems, and 15 Veterans
hospitals.
Patients—All 675 patients diagnosed with stage III colon cancer during 2003-2005 who
underwent surgical resection were followed up to 15 months post-diagnosis.
Main outcome measures—Chemotherapy regimen, dose, duration and annualized mean
number of adverse events stratified by age.
Results—Half of the 202 patients >=75 years received adjuvant chemotherapy compared with
87% of 473 younger patients (diff 37%, 95% CI 30%-45%). Among adjuvant chemotherapy users,
14 (14%) of patients >=75 years and 178 (44%) of younger patients received a regimen containing
oxaliplatin (diff 30%, 95% CI 21%-38%). Older patients were less likely to continue. By 150
days, 99 (40%) patients >= 65 years and 68 (25%) younger patients had discontinued
chemotherapy (diff 15%, 95% CI 7%-23%). Overall, 162 (24%) patients had at least one adverse
clinical event, with more events among patients treated with vs. without adjuvant chemotherapy
(mean 0.394 vs. 0.160, diff 0.234, 95% CI 0.11-0.36, p<0.001). Among adjuvant chemotherapy
users, adjusted rates of late clinical adverse events show a reverse U-distribution with lower rates
for patients >= 75 years (0.277) versus for younger patients (0.345 for 18-54, 0.519 for 55-64, and
0.446 for 65-75 years, p=0.008 for any age effect).
Conclusions—Older patients in the community receive less toxic and shorter chemotherapy
regimens, and those treated had fewer adverse events than younger patients. The effect of these
differences on clinical outcomes is not clear.
Keywords
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settings
Randomized trials have shown reductions in cancer death and recurrence in patients with
stage III colon cancer treated with adjuvant chemotherapy.1-4 A pooled analysis of trials
comparing 5-fluorouracil (5-FU) and leucovorin or levamisole against no adjuvant
chemotherapy reported a 24% reduction in mortality and a 32% reduction in disease
recurrence across all age categories of chemotherapy users, indicating that the effectiveness
of adjuvant chemotherapy with 5-FU-based regimens is similar in elderly and younger
patients.5 Based upon selected patients accrued to clinical trials, several analyses have
shown a disease-free survival advantage associated with the addition of oxaliplatin to
standard 5-FU and leucovorin; but with increased toxicity which does not appear to vary by
age.4, 6, 7
In practice elderly patients with stage III colon cancer are much less likely to receive
adjuvant chemotherapy8-14 despite evidence that adjuvant therapy with 5-FU is effective
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across the spectrum of age. Physicians cite the lack of RCTs evaluating the effectiveness of
adjuvant chemotherapy for large numbers of patients over age 80 as an important reason for
not treating the elderly. Additionally, physicians often cite comorbid conditions and drug
toxicities, in conjunction with the additional effort and expense of treating older patients, as
the most common reasons for not treating the elderly with adjuvant chemotherapy.11, 13, 15
Patients in clinical trials are systematically different from those in the community, where
most decisions about chemotherapy are made. Compared with patients diagnosed nationally
with stage III colon cancer, trial patients are younger, more likely to be white, and less likely
to have comorbidities or functional impairment than community-dwelling adults.8, 11
Therefore, we analyzed the use of adjuvant chemotherapy and clinical adverse events by age
in a large multi-regional cohort of patients with stage III colon cancer. We accounted for
multiple dimensions of patients’ burden of illness, intensity of chemotherapy regimen, and
other clinical variables that might affect adverse events in these patients.
METHODS
Study design
The Cancer Care Outcomes Research and Surveillance (CanCORS) study examined care
delivered to population- and health system-based cohorts of patients, including 4713 patients
newly diagnosed with colorectal cancer between 2003 and 2005 and followed for up to 15
months.16 Patients were living in Northern California, Los Angeles County, North Carolina,
or Alabama, or received care in one of five large health maintenance organizations or 15
Veterans Administration hospitals.11, 15-19 Human subjects committees at all participating
institutions approved the study. All interviewed participants provided verbal consent based
on interviewer scripts approved by relevant IRBs, and all living patients provided written
consent for medical record review.
Study sample
This analysis included all 675 patients with stage III colon cancer who underwent surgical
resection and had survey and medical record data (Figure 1). We used data from a baseline
patient survey approximately four months after diagnosis and from the review of medical
records from multiple providers from three months before to 15 months after diagnosis.16
Surveys were conducted in English, Spanish, and Chinese and included four options: a 45
minute full survey (71%), a 20-minute brief survey for patients too sick to complete the full
one (13%), and two surrogate surveys, one for patients alive but too sick to participate (9%)
and one for patients deceased at the time of the baseline survey (7%). Self-reported patient
demographics including age, gender, race/ethnicity, income and marital status were included
to control for sociodemographic factors related to access and utilization. We used data from
medical records to assign AJCC collaborative stage20 to 76% of study patients; where
complete stage data were not available from medical records, we obtained collaborative
stage data from participating cancer registries.
Preexisting Burden of Illness
We assessed comorbidity from 3 months before diagnosis to the time of initial treatment
from the medical record using the ACE-27 instrument.21, 22 Patients’ recalled health status
during the four weeks prior to diagnosis was obtained from the baseline survey.17 Other
measures of patient-level burden of illness included a history of prior cancer and assignment
of a do-not-resuscitate order prior to the first hospitalization with an admission date >30
days after surgical resection.
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We defined adverse clinical events as the first occurrence of each of a subset of 39 clinical
diagnoses that could reliably be abstracted from the medical record and that were important
enough to adversely affect the patient's process of care, quality of life and/or survival as
described in Table 3. Events were included regardless of whether the events could be
directly attributed to treatment.
Using the same list of clinical diagnoses, we defined early and late adverse events. Those
that occurred prior to 30 days after surgical resection were considered early and were used
as predictor variables. Events that occurred between 31 days after surgical resection and 15
months after diagnosis were used as a surrogate for events attributable to chemotherapy and
considered late. (See Appendix B for complete listing of late adverse events.) We defined
outcomes as annualized late adverse event rates, calculated by dividing the sum of each
patient's unique clinical events by their total number of days alive subsequent to 30 days
after resection.
Adjuvant Chemotherapy use
Chemotherapy was defined as adjuvant if the first dose was administered within 6 months
after surgical resection and prior to any cancer recurrence. To characterize the type of
chemotherapy, we classified initial chemotherapy regimens into oxaliplatin-containing, non-
oxaliplatin-containing, and unknown. Chemotherapy initiation was categorized as days from
surgical resection to first chemotherapy. Patients were considered to have received reduced-
dose chemotherapy if their initial regimen included at least one dose of: 5FU bolus <350
mg/m2; 5FU continuous <600 mg/m2; capecitabine <850 mg/m2; or oxaliplatin <75 mg/m2.
Duration of treatment was categorized by specifying the proportion of patients discontinuing
chemotherapy by a specified date (e.g. before six months, See Figure 2), and also as a
continuous variable counting the number of days from first to last chemotherapy dose.
Validity of Record Abstraction
We validated the accuracy of medical record abstraction by comparing 146 medical record
abstractions with gold standard records, specified by the research team. The mean agreement
score was 0.825 (SD 0.222).
Statistical analyses
We used univariate analyses to describe study patients, their chemotherapy initiation, initial
regimen, dose, duration, and adverse event rates using CanCORS core 1.07 and medical
record abstraction 1.9 data sets. All significance tests were two-sided at the 0.05 level.
Analyses used SAS 9.1.3 and Stata 9.2.
We used a Poisson model to describe the count of unique patient-level adverse events with
exposure defined as their total number of days alive subsequent to 30 days post-resection.23
Finally, we used recycled predictions, a method that produces adjustments in the event rate
scale,24 to estimate the yearly late adverse event rates of patients with vs. without
chemotherapy stratified by age.
Independent variables included age; gender; race/ethnicity; income; marital status; burden of
illness (survey type, pre-diagnosis health status, comorbidity, early adverse events, prior
cancer, and early DNR order); initial adjuvant chemotherapy regimen (with or without
oxaliplatin, missing regimen, or none), chemotherapy initiation date, reduced dose
chemotherapy, chemotherapy duration less than six months, and number of days from first
to last chemotherapy. We treated sites as fixed rather than random effects, because we
studied a limited number of sites that were purposively selected rather than sampled from a
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larger number of sites. The model also adjusted for calendar time trends and days from
diagnosis to survey.
We compared patients age ≥75 with patients in younger age categories and tested for
interactions between age and survey type, pre-diagnosis health status, comorbidity, and
postoperative adverse events; between age and chemotherapy type (oxaliplatin vs. not); and
between comorbidity and chemotherapy (oxaliplatin vs. not). Two statistically significant
interactions were included in the model: youngest age category*no adjuvant chemotherapy
and surrogate survey*non-oxaliplatin chemotherapy use.
Sensitivity analyses
We assessed whether results were sensitive to the model chosen by fitting an alternative
model using inverse probability of treatment weights based on propensity score for receiving
any chemotherapy, and separately for receiving individual chemotherapy regimens.25, 26 No
statistically significant differences between results of the primary and alternate model were
observed. Results were also similar when we constrained the close of the observation
window for adverse outcomes to six months after surgical resection and again separately by
the date of the last documented medical record visit. Finally, results were similar when we
omitted do-not-resuscitate order (DNR) from the model, and when we omitted deceased
patients (7%) whose baseline survey was completed by a surrogate.
RESULTS
Study Cohort
Within the study cohort, those 75 years and older were less likely to be non-white [47 (23%)
vs. 169 (36%)], to be married or living with a partner [103 (51%) vs. 326 (69%)], and to
report annual income more than $20,000 compared with younger patients [144 (71%) vs.370
(78%), p<0.001 for all three comparisons, Table 1). Fewer than 48 (10%) patients <75 years
were unable to complete the survey because of sickness or death, while 66 (33%) patients
aged 75 or older were unable (p<0.001). 30 (15%) patients at least 75 years had no
comorbidity, a lower proportion than noted in other age groups [62 (44%), 51 (32%), and 33
(19%) respectively for three younger age cohorts, p<.001). Early clinical adverse events
were more prevalent among patients at least 75 years with mean score 0.54 for >=75 vs. 0.35
for patients <75 years, (diff 0.19, 95% CI 0.05-0.34).
Patient Selection for Adjuvant Chemotherapy
Overall, patients receiving adjuvant chemotherapy were significantly less burdened with
comorbid illness. Among adjuvant chemotherapy users, 150 (29%) had no comorbidity
compared with 26 (16%) among patients not receiving chemotherapy (diff 13%, 95% CI
6-20, Table 2).
Initial Chemotherapy Regimen
Overall, 513 (75%) of the 675 stage III colon cancer patients received any adjuvant
chemotherapy. Half of the 202 patients >=75 years received adjuvant chemotherapy
compared with 87% of 473 younger patients (diff 37%, 95% CI 30%-45%, p<.001). Among
adjuvant chemotherapy users, 14 (14%) of patients >=75 years and 178 (44%) of younger
patients used an oxaliplatin-containing regimen (diff 30%, 95% CI 21%-38%).
Chemotherapy Initiation, Dose and Duration
Patients initiated adjuvant therapy a median of 47.3 days from surgery (51 days for patients
at least 75 years and 46 days for those<75 years). Overall, 18% of patients had at least one
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drug in their initial regimen delivered at a reduced dose and this did not vary according to
age. Although the recommended duration of stage III adjuvant chemotherapy regimens is at
least 24 weeks,27-29 by 21 weeks (150 days) from adjuvant chemotherapy initiation, more
than one-quarter of patients had discontinued treatments. Patients age 65 years and older
were more likely than younger patients to discontinue chemotherapy at all follow-up times.
This effect was statistically significant within 30 and beyond 90 days after initiating
chemotherapy (Figure 2). For example, by 150 days, 99 (40%) patients >= 65 years and 68
(25%) younger patients had discontinued chemotherapy (diff 15%, 95% CI 7%-23%).
Rate of Late Clinical Adverse Events
Table 3 summarizes the frequency of adverse events according to treatment. Overall, 162
patients (24%) had at least one late adverse event. Late events occurred in more than twice
as many patients receiving versus not receiving adjuvant chemotherapy [142 (28%) vs. 21
(13%), diff 15%, 95% CI 8-21, Table 3]. The mean number of unique adverse events was
also higher for adjuvant chemotherapy users versus non-users (0.39 vs. 0.16,, diff 0. 23,
95%, CI 0.11-0.36).
Late adverse events were associated with adjuvant chemotherapy (both oxaliplatin and non-
oxaliplatin regimens) as well as surrogate survey type, early DNR order, and female gender
(all p<0.05), after adjustment for other variables in the model (See Appendix B). Among
adjuvant chemotherapy users (light colored bar in Figure 3.A), adjusted rates of late clinical
adverse events show a reverse U-distribution across increasing age categories with the oldest
patients having a lower adverse event rate than patients in the other age categories (0.345,
0.519, 0.446, 0.277; p=0.0080 for any age effect, and p=0.0125 for analysis of the effect of
age categories beyond that explained by the youngest age category*no chemotherapy
interaction). Regardless of whether the model included adjuvant chemotherapy as a single
indicator variable, or as oxaliplatin vs. non-oxaliplatin regimens, adjuvant chemotherapy
significantly predicted late adverse events (0.372 with adjuvant vs. 0.203 without adjuvant
chemotherapy, diff 0.169, 95% CI 0.067-0.271). Across all tested age regimens, the
inverted-U pattern of late adverse effects was preserved.
Late adverse event rates were 50% higher with oxaliplatin vs. non-oxaliplatin containing
regimens (0.580 vs. 0.403, diff 0.177, 95% CI 0.071-0.283, Figure 3B). The higher rates of
late adverse events with oxaliplatin were accounted for by the higher rates of neuropathy
among oxaliplatin users.
DISCUSSION
We analyzed adverse events in stage III colon cancer patients in relation to adjuvant
chemotherapy treatment and age. Patients in our study were enrolled from defined
populations and healthcare systems throughout the United States. Therefore these results
describe care across diverse settings and patients in academic centers and community
practices, complementing descriptions of adverse events in randomized controlled trials in
which patients are highly selected.
From these diverse settings and patients, we found that use of adjuvant chemotherapy
differed substantially from evidence-based recommendations, especially for older patients.
Despite evidence from selected patients accrued to clinical trials showing improved
outcomes for patients receiving adjuvant chemotherapy regardless of age, only 50% of
patients age 75 and older initiated this treatment. Starting doses were lower than in the
standard regimens tested in trials for 18% of patients, but such dose attenuation did not vary
by age. Older patients were much less likely to receive oxaliplatin-containing regimens,
which have been shown in clinical trials of patients <75 years to be more effective, but also
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more toxic, than standard regimens.4, 7 In contrast to trial-based recommendations for a six-
month course of adjuvant chemotherapy,27-29 only two-thirds of patients were still using
chemotherapy at six months, with higher discontinuation rates with increasing age. Among
patients receiving adjuvant chemotherapy, older patients did not experience more adverse
events than younger patients in either unadjusted analysis or after controlling for
comorbidity and treatment characteristics.
Older patients receiving adjuvant chemotherapy in our study had less burden of illness than
age-matched patients not receiving chemotherapy. Selection of less vulnerable patients
might be one reason that older patients tolerated adjuvant chemotherapy better than younger
patients. It is reassuring that adjustment for six dimensions of burden of illness beyond
measures of demographics and chemotherapy initiation, regimen type, and duration, did not
alter the finding that older patients were no more likely to have late adverse events than
younger patients. We also confirmed our results with propensity score methods as a means
to reduce selection bias by equating treated and untreated patients based upon observable
characteristics.30 Nevertheless, residual confounding remains possible and some part of our
results may reflect selection of healthier elderly patients for chemotherapy use. In this
regard, our population-based findings are consistent with those of published clinical trials
and observational studies demonstrating that older patients with stage III colon cancer
receiving chemotherapy do not experience more adverse events than younger patients.1-5, 8,
10, 12, 31 This consistency of findings should reassure clinicians and patients who are
concerned that toxicities may outweigh benefits, especially for older patients.
Adjuvant chemotherapy is generally intended to prevent disease recurrence and prolong
survival for patients expected to live at least five years; it is not usually indicated for patients
with more limited life expectancy, regardless of age. Of note, women and men who reach
age 70 have an additional median life expectancy of 16.2 and 13.7 years respectively, and
those who survive to age 80 have an additional life expectancy of 9.8 and 8.2 years,8, 32-34
suggesting that adjuvant chemotherapy should be considered for many older patients.
However, the dearth of clinical trial data for older patients should be noted.
Older patients who received chemotherapy, including 41 patients >=80 years old, did not
suffer higher rates of adverse events than younger patients, but the duration of follow-up of
our cohort is not yet sufficient to know whether survival benefits expected from adjuvant
chemotherapy were preserved for older patients using lower doses and shorter durations of
treatment.5, 35 We plan to follow-up this cohort for measures of clinical benefit to learn
whether the lower doses and shorter courses of treatment represent a clinical advance for
older patients, or whether these modified regimens affect cancer recurrence and disease-free
survival.
Our findings underscore that practical clinical trials of adjuvant chemotherapy for older
patients with stage III colon cancer are needed, including patients with comorbidities and
functional impairment.36 This would be consistent with the nation's commitment to
comparative effectiveness research. Such trials should include patients across diverse
community practice settings regardless of whether they have comorbidity.37 Our data
suggest that physicians would be more comfortable enrolling their patients in such a trial if
the treatment arm involved standard 5FU-based chemotherapy without the addition of
oxaliplatin. Recent data appear to support this position. An analysis of aggregate trial data,
published in abstract form, reported that among patients over 70, newer adjuvant regimens
were no more effective than standard 5-FU/leucovorin.35
Our study documents the safety of adjuvant chemotherapy for older patients across diverse
community settings, while also noting only half of older patients receive adjuvant
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chemotherapy and those who do, receive shorter than recommended duration. Strategies to
help clinicians uncertain about the safety of adjuvant chemotherapy for older patients with
comorbidity could increase the likelihood that evidence-based chemotherapy benefits are
realized in population-based settings. Using decision support tools built upon published
trials and population based analyses such as these, can help clinicians to predict
effectiveness of chemotherapy, even for patients with comorbid conditions and advanced
age.37, 38 Systematic monitoring of symptoms and signs among chemotherapy users,
combined with interventions to evaluate and treat these clues, could help clinicians to
support patients achieve the goal of completing evidence-based treatment dosage and
duration goals. While it may not be possible to fully avoid diarrhea with 5-flourouracil or
neuropathy with oxaliplatin, clinicians who identify symptoms and signs early and take steps
to avoid these early signals from cascading into serious adverse outcomes may enable their
patients to complete recommended treatment courses, while also improving quality of life
for patients. In aggregate, these results can help clinicians and patients to estimate,
anticipate, and optimize the safety of adjuvant chemotherapy for elderly patients with stage
III colon cancer in diverse practice settings, increasing the likelihood that evidence-based
chemotherapy benefits are realized in population-based settings.
Our study has several strengths. Patients were identified in representative populations or
health systems with relatively few exclusion criteria and so are likely to broadly represent
care in the community. The sample size was large enough to yield relatively stable estimates
of rates in subgroups defined by treatment and age (including 109 patients >=80 years), and
to support modeling for other covariates. We included a rich set of adverse events that are
likely to affect patient's quality and quantity of life, and that occurred during the time
window that corresponds with adjuvant chemotherapy use. Adverse events were identified
from the various physicians caring for these cancer patients using inpatient and ambulatory
records from oncologists, surgeons, other specialists and primary care physicians.
Our study also has limitations. Follow-up is not yet complete for analyses of recurrence rates
and longer-term survival. Although we adjusted for a rich set of covariates using rigorous
statistical methods, patients might have been selected for treatment according to unmeasured
characteristics and these might have also been related to adverse events. We collected
clinically important adverse events rather than using the Common Toxicity Criteria (CTC)
grading scheme developed for clinical trials.39 Of note, CTC's were designed to be collected
prospectively by trial staff, so that its classification scheme is not well-suited for abstraction
from medical records alone. Nevertheless, our abstracted rate of neuropathy (11%) among
patients <75 years is consistent with the prevalence of Grade III neuropathy noted in the
MOSAIC trial.4 The use of different measures and data sources means we cannot directly
compare the event rates we observed with clinical trials involving the same agents.
However, because we focused on events that were clinically important rather than transient
symptoms or isolated abnormal laboratory values, our data may be even more appropriate
for informing clinical decision-making with future patients.
Our results suggest that based upon age alone, adjuvant chemotherapy need not be avoided
for patients with stage III colon cancer who are expected to survive at least five years.
Understandably, clinicians and patients are concerned about how the substantial burden of
illness typically associated with older age could influence outcomes associated with
chemotherapy. However, our results indicate that older patients receiving adjuvant
chemotherapy in diverse settings appear to tolerate the treatment without an increased risk of
adverse events compared with younger patients. Among older patients selected by clinicians
for adjuvant chemotherapy, usually the less toxic non-oxaliplatin based regimens, this
analysis shows older patients tolerate adjuvant chemotherapy, although more often with
earlier discontinuation of treatment. However, this empirical analysis leaves open the
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question of whether other older patients who were untreated might also tolerate and benefit
from the use of adjuvant chemotherapy.
Based upon randomized trials and now corroborated in a multisite community sample, use
of adjuvant chemotherapy among selected older patients appears safe. However, avoiding
chemotherapy and delivering doses and durations lower than recommended based on the
definitive clinical trials may prevent older patients from achieving the full expected benefits
of adjuvant chemotherapy.
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Late1 Clinical Adverse Events Day 31 Post Surgical Resection Through 15 Months Post
Diagnosis for Patients with Stage 3 Colon Cancer (Unadjusted)
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Poisson Models Predicting Late Adverse Event Rates According to Specification of
Adjuvant Chemotherapy
Model defines chemotherapy






Regimen type (vs. none)
Coefficient1 p-value Coefficient1 p-value
Male gender 0.3024 0.049 0.3360 0.03
Married or living together -0.2022 0.192 -0.2191 0.155
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Regimen type (vs. none)
Coefficient1 p-value Coefficient1 p-value
Hispanic -0.3476 0.199 -0.3229 0.241
African American -0.2417 0.241 -0.1858 0.371
Asian -0.3824 0.237 -0.3460 0.291
Brief survey 0.0061 0.978 0.0133 0.953
Surrogate survey 1.1587 0.000 0.9276 0.001
Age <55 years 0.2769 0.268 0.0294 0.91
Age 55-64 years 0.6660 0.002 0.5101 0.023
Age 65-74 years 0.4623 0.023 0.3469 0.094
Income <$20,000 -0.2127 0.323 -0.2468 0.253
Income $20-40,000 0.1622 0.334 0.2223 0.185
Pre-diagnosis health status 0.0048 0.418 0.0031 0.598
No comorbidity 0.1037 0.68 0.0323 0.899
Mild comorbidity 0.0137 0.954 -0.0510 0.83
Moderate comorbidity 0.4361 0.082 0.4131 0.102
Early adverse outcome score (<=30 days post
resection)
0.0236 0.761 0.0435 0.566
History of prior cancer -0.1081 0.63 -0.0837 0.71
Early do-not-resuscitate order 1.9675 0.000 1.9225 0.000
Site 1 0.0096 0.976 0.0170 0.957
Site 2 -0.1521 0.678 -0.3179 0.389
Site 3 -0.4737 0.175 -0.5085 0.153
Site 4 0.4752 0.139 0.2613 0.419
Site 6 0.0982 0.752 -0.1031 0.745
Calendar date for colon cancer diagnosis 0.0311 0.392 -0.0363 0.363
Adjuvant chemotherapy 1.0021 0.016
Oxaliplatin-based regimen 1.5078 0.001
Non-oxaliplatin-based regimen 0.6485 0.13
<55years*no adjuvant chemotherapy use 1.1025 0.097 1.2772 0.054
Non-oxaliplatin-regimen*surrogate survey 0.3611 0.264 0.9230 0.008
Chemotherapy initiation date (# days after
diagnosis)
-0.0022 0.455 -0.0029 0.344
Missing adjuvant chemotherapy regimen 1.2150 0.023
Reduced dose adjuvant chemotherapy -0.2942 0.145 -0.3815 0.061
Chemotherapy duration >=6 months 0.1614 0.422 0.1800 0.371
Count of # of days from 1st to last chemotherapy
dose
0.0003 0.738 0.0001 0.891
Intercept -9.2339 0 -8.6081 0
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Coefficients are in the log scale. Positive signs indicate an increased rate of adverse events for the higher value of the
independent variable and negative signs indicate a decreased rate of adverse events for the higher value of the independent
variable.
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Figure 2. Cumulative Proportions of Patients Discontinuing Chemotherapy by Specified Day by
Age
1Y-axis shows % patients discontinuing chemotherapy at specified time period.
2X-axis shows the time window during which adjuvant chemotherapy is discontinued. For
each age-specific curve, the data points show the % patients who have discontinued adjuvant
chemotherapy by the end of the specified time window. Across all of the time windows
listed in the x-axis, the n associated with the denominator is constant and includes all
patients who initiate adjuvant chemotherapy (n=513).
3For example, within the time window from 1-30 days following adjuvant chemotherapy
initiation, across respectively increasing age categories, 2, 3, 7, and 10% of patients have
discontinued treatment (p=0.014).
*p-values indicate differences in probability of chemotherapy discontinuation by age for
surviving patients as of 30, 60, 90, 120, and 150 days after chemotherapy initiation using
Cox proportional hazard model. As noted, older patients are significantly more likely to
discontinue chemotherapy at all time points (i.e., 30, 60, 90, 120, and 150 days). Note that
the % patients having last chemotherapy date as of 180 days does not differ by age.(not
shown).
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Figure 3. Adjusted Yearly Late Adverse Event Rates1
1Poisson Models are adjusted for: gender (male); married or living together; race/ethnicity
(Hispanic, Black, Asian with White as reference group); survey type (brief, surrogate- with
full survey as reference group); age (<55, 55-64, 65-74 years- with >=75 years as reference
group); income ($20,000 and $20-40,000- with >$40,000 as reference group); pre-diagnosis
health status; comorbidity (none, mild, moderate- with severe as reference group); early
(from 90 days before to <=30 days post-surgical resection); history of prior cancer; early do-
not-resuscitate order; study sites; calendar date for colon cancer diagnosis; adjuvant
chemotherapy (vs. none); number of days from diagnosis to chemotherapy initiation;
reduced dose adjuvant chemotherapy; chemotherapy duration >=6 months; and count of # of
days from 1st to last chemotherapy dose). For Figure 3.A, adjuvant chemotherapy is defined
as any adjuvant chemotherapy with no adjuvant chemotherapy as reference group. For
Figure 3.B, adjuvant chemotherapy is defined as oxaliplatin-containing, non-oxaliplatin-
containing, or missing regimen vs. none. Regardless of whether the model included adjuvant
chemotherapy as a single dummy variable (Figure 3.A) or as regimen-specific dummies (not
shown), adjuvant chemotherapy significantly predicts late adverse events.
2 Among adjuvant chemotherapy users (light colored bar in Figure 3.A), adjusted rates of
late clinical adverse events show a reverse U-distribution across increasing age categories
with the oldest patients having a lower adverse event rate than patients in the other age
categories (0.345, 0.519, 0.446, 0.277; p=0.0080 for any age effect, and p=0.0125 for
analysis of the effect of age categories beyond that explained by the youngest age
category*no chemotherapy interaction). This p-value corresponds to a multiple degree of
freedom likelihood ratio test for which there is no difference statistic and corresponding
confidence interval,, similar to an F-test in an ANOVA model.
3Among non-chemotherapy users (lower square-marked curve in Figure 3.A), late adverse
events are highest among youngest patients (p=0.0125).
4Figure 3.B shows adjusted yearly late adverse event rates are significantly higher for
patients using oxaliplatin (upper diamond-marked solid curve in Figure 3.B) as compared
with patients using non-oxaliplatin based regimens (lower triangle-marked solid curve in
Figure 3.B) across all four age categories (p<.001).
5Adjusted yearly late adverse event rates differ significantly among oxaliplatin users (upper
diamond-marked solid curve vs. square-marked hyphenated line, p = 0.015) according to
whether neuropathy is included or excluded in the definition of the adverse events. Adjusted
yearly late adverse event rates for oxaliplatin users vs. non-users are higher when
neuropathy is included in the model (upper diamond-marked solid curve in Figure 3.B vs.
lower triangle-marked solid curve in Figure 3.B). Once neuropathy is excluded from the list
of late adverse events, there is no difference between oxaliplatin and non-oxaliplatin users
(No difference between middle square-marked dotted curve and lower triangle-marked solid
curve in Figure 3.B).
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Table 3
Late1 Clinical Adverse Events Day 31 Post Surgical Resection through 15 Months Post Diagnosis for Patients
with Stage 3 Colon Cancer (Unadjusted)
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